Ligand Pharmaceuticals Incorporated (LGND) DCF Valuation
- ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
- ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
- ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
- ✓ No Se Necesita Experiencia; Fáciles De Seguir
Ligand Pharmaceuticals Incorporated (LGND) Bundle
Enhance your investment choices with the (LGND) DCF Calculator! Utilize actual Ligand Pharmaceuticals financial data, adjust growth projections and expenses, and instantly observe how these modifications influence the intrinsic value of (LGND).
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 120.3 | 186.4 | 277.1 | 196.2 | 131.3 | 144.9 | 159.9 | 176.4 | 194.7 | 214.8 |
| Revenue Growth, % | 0 | 54.98 | 48.66 | -29.19 | -33.09 | 10.34 | 10.34 | 10.34 | 10.34 | 10.34 |
| EBITDA | 38.0 | 69.1 | 133.2 | 54.4 | 101.7 | 64.3 | 71.0 | 78.3 | 86.4 | 95.3 |
| EBITDA, % | 31.6 | 37.04 | 48.05 | 27.72 | 77.47 | 44.38 | 44.38 | 44.38 | 44.38 | 44.38 |
| Depreciation | 43.7 | 28.0 | 41.3 | 43.4 | 37.4 | 33.9 | 37.4 | 41.2 | 45.5 | 50.2 |
| Depreciation, % | 36.36 | 15 | 14.92 | 22.11 | 28.49 | 23.38 | 23.38 | 23.38 | 23.38 | 23.38 |
| EBIT | -5.7 | 41.1 | 91.8 | 11.0 | 64.3 | 30.4 | 33.6 | 37.1 | 40.9 | 45.1 |
| EBIT, % | -4.76 | 22.04 | 33.13 | 5.61 | 48.98 | 21 | 21 | 21 | 21 | 21 |
| Total Cash | 1,069.9 | 411.2 | 341.1 | 211.9 | 170.3 | 144.9 | 159.9 | 176.4 | 194.7 | 214.8 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 41.7 | 59.1 | 91.6 | 35.0 | 39.3 | 42.7 | 47.1 | 52.0 | 57.3 | 63.3 |
| Account Receivables, % | 34.71 | 31.68 | 33.07 | 17.85 | 29.94 | 29.45 | 29.45 | 29.45 | 29.45 | 29.45 |
| Inventories | 7.3 | 26.5 | 27.3 | 13.3 | 24.0 | 16.0 | 17.6 | 19.5 | 21.5 | 23.7 |
| Inventories, % | 6.07 | 14.21 | 9.86 | 6.77 | 18.25 | 11.03 | 11.03 | 11.03 | 11.03 | 11.03 |
| Accounts Payable | 2.4 | 3.8 | 8.4 | 5.3 | 2.4 | 3.4 | 3.7 | 4.1 | 4.5 | 5.0 |
| Accounts Payable, % | 2.01 | 2.03 | 3.03 | 2.7 | 1.85 | 2.33 | 2.33 | 2.33 | 2.33 | 2.33 |
| Capital Expenditure | -2.6 | -4.5 | -8.8 | -17.9 | -3.5 | -5.6 | -6.2 | -6.9 | -7.6 | -8.4 |
| Capital Expenditure, % | -2.12 | -2.39 | -3.16 | -9.13 | -2.68 | -3.9 | -3.9 | -3.9 | -3.9 | -3.9 |
| Tax Rate, % | 18.07 | 18.07 | 18.07 | 18.07 | 18.07 | 18.07 | 18.07 | 18.07 | 18.07 | 18.07 |
| EBITAT | -4.5 | 11.6 | 110.9 | -1.6 | 52.7 | 17.6 | 19.4 | 21.4 | 23.7 | 26.1 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | -10.0 | .0 | 114.7 | 91.4 | 68.8 | 51.4 | 44.8 | 49.5 | 54.6 | 60.3 |
| WACC, % | 8.68 | 8.66 | 8.69 | 8.65 | 8.68 | 8.67 | 8.67 | 8.67 | 8.67 | 8.67 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 202.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 61 | |||||||||
| Terminal Value | 921 | |||||||||
| Present Terminal Value | 608 | |||||||||
| Enterprise Value | 811 | |||||||||
| Net Debt | -17 | |||||||||
| Equity Value | 827 | |||||||||
| Diluted Shares Outstanding, MM | 18 | |||||||||
| Equity Value Per Share | 46.59 |
What You Will Receive
- Comprehensive Financial Model: Utilize Ligand Pharmaceuticals' (LGND) actual data for an accurate DCF valuation.
- Complete Forecasting Control: Modify revenue growth, profit margins, WACC, and other crucial parameters.
- Real-Time Calculations: Automatic updates provide immediate insights as you adjust inputs.
- Professional-Grade Template: An expertly crafted Excel file tailored for high-quality valuation.
- Flexible and Reusable: Designed for adaptability, allowing for repeated application in detailed forecasting.
Key Features
- 🔍 Real-Life LGND Financials: Pre-filled historical and projected data for Ligand Pharmaceuticals Incorporated.
- ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
- 📊 Professional DCF Valuation: Built-in formulas calculate Ligand’s intrinsic value using the Discounted Cash Flow method.
- ⚡ Instant Results: Visualize Ligand’s valuation instantly after making changes.
- Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.
How It Works
- Step 1: Download the Excel file.
- Step 2: Review Ligand Pharmaceuticals Incorporated’s pre-filled financial data and forecasts.
- Step 3: Modify key inputs such as revenue growth, WACC, and tax rates (highlighted cells).
- Step 4: Observe the DCF model update in real-time as you adjust your assumptions.
- Step 5: Analyze the outputs and utilize the results for your investment strategies.
Why Choose This Calculator?
- Designed for Experts: A sophisticated tool utilized by researchers, investors, and financial analysts.
- Comprehensive Data: Ligand Pharmaceuticals' (LGND) historical and projected financials included for precision.
- Flexible Scenario Analysis: Effortlessly test various forecasts and assumptions.
- Insightful Outputs: Automatically computes intrinsic value, NPV, and essential metrics.
- User-Friendly: Step-by-step guidance simplifies the entire process.
Who Should Use This Product?
- Professional Investors: Develop comprehensive and accurate valuation models for analyzing portfolios focused on Ligand Pharmaceuticals (LGND).
- Corporate Finance Teams: Evaluate valuation scenarios to inform strategic decisions within their organizations.
- Consultants and Advisors: Deliver precise valuation insights to clients interested in Ligand Pharmaceuticals (LGND).
- Students and Educators: Utilize real-world data to learn and teach financial modeling techniques related to the biotech sector.
- Biotech Enthusiasts: Gain insights into how companies like Ligand Pharmaceuticals (LGND) are valued in the investment landscape.
What the Template Contains
- Operating and Balance Sheet Data: Pre-filled Ligand Pharmaceuticals historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
- WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
- DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
- Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
- Key Ratios: Includes profitability, leverage, and efficiency ratios for Ligand Pharmaceuticals (LGND).
- Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.